SCHEMBL1490771

SCHEMBL1490771

CC(C)Cn1c(CCl)nc2cnc3ccccc3c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
NPSR1 Q6W5P4 1/20 0.42
TLR7 Q9NYK1 5/20 0.41
POLB P06746 1/20 0.41
HRH2 P25021 1/20 0.41
ADRA1D P25100 1/20 0.41
HTR2A P28223 1/20 0.41
ADORA2A P29274 1/20 0.41
ADRA1A P35348 1/20 0.41
NUDT1 P36639 1/20 0.41
HTR2B P41595 1/20 0.41
PDE4D Q08499 1/20 0.41
KCNH2 Q12809 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TLR8 Q9NR97 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PDE10A Q9Y233 1/20 0.38
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10589469 0.88 TLR7 (0.52) LMNANPSR1TLR7POLBHRH2
SCHEMBL8565615 0.88 TSHR (0.47) LMNANPSR1TLR7POLBHRH2
SCHEMBL6719567 0.87 TLR7 (0.43) LMNANPSR1TLR7POLBHRH2
SCHEMBL6719536 0.85 L3MBTL1 (0.42) LMNANPSR1TLR7POLBHRH2
SCHEMBL6723871 0.85 TLR7 (0.52) LMNANPSR1TLR7POLBHRH2
SCHEMBL6726435 0.84 LMNA (0.42) LMNANPSR1TLR7POLBHRH2
SCHEMBL6722232 0.83 TLR7 (0.50) LMNANPSR1TLR7POLBHRH2
SCHEMBL6724102 0.83 TLR7 (0.40) LMNANPSR1TLR7POLBHRH2
SCHEMBL1490883 0.83 TLR7 (0.37) LMNATLR7
SCHEMBL6719520 0.83 TLR7 (0.42) LMNANPSR1TLR7POLBHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598192-B2 Hydroxylamine substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-12-03 US disclosed
US-7968563-B2 Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-06-28 US disclosed
US-7897767-B2 Oxime substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-20100069427-A9 Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2010-03-18 US disclosed
EP-1682544-A4 HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2009-05-06 EP disclosed
US-20090105295-A1 HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-04-23 US disclosed
US-20090062328-A1 Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-03-05 US disclosed
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. 2009-02-12 US disclosed
EP-1685129-A4 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2008-10-22 EP disclosed
US-20080015184-A1 Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-01-17 US disclosed
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods COLEY PHARMACEUTICAL GROUP, INC. 2007-11-08 US disclosed
EP-1846405-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED IMIDAZO 4,5-C RING COMPOUNDS AND METHODS 3M Innovative Properties Company (US) 2007-10-24 EP disclosed
WO-2006086634-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-17 WO disclosed
EP-1685129-A2 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M Innovative Properties Company (US) 2006-08-02 EP disclosed
EP-1682544-A2 HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS 3M Innovative Properties Company (US) 2006-07-26 EP disclosed
WO-2006009832-A1 SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-01-26 WO disclosed
WO-2005123079-A2 UREA SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-12-29 WO disclosed
WO-2005048945-A2 HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 WO disclosed
WO-2005048933-A2 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods IL2, IL4, IRF3 LMNA 4207/4885NPSR1 3420/4885TLR7 55/4885
US-20090105295-A1 HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES IL2, IL4, IFNG LMNA 4272/4885NPSR1 3371/4885TLR7 54/4885
US-20100069427-A9 Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods IFNG, IL4, IRF3 LMNA 2435/4885NPSR1 2247/4885TLR7 76/4885
US-20090062328-A1 Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods IFNG, IL4, IRF3 LMNA 2435/4885NPSR1 2247/4885TLR7 76/4885
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES IFNG, IL2, IRF3 LMNA 4467/4885NPSR1 3628/4885TLR7 33/4885
US-20080015184-A1 Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines IL2, EIF2AK2, IL4 LMNA 3978/4885NPSR1 4479/4885TLR7 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.